Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics
RSS SUMMARY · AGGREGATED FROM TWSJ
The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche taking the larger share.
The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche taking the larger share.
The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche taking the larger share.
Continue Reading
The full story continues on The Wall Street Journal.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
TWSJ
Business
Ingredion to Take Over Tate & Lyle in $3.6 Billion Deal
TWSJ·1h ago·3 min read
World News
Chinese AI Startup StepFun Set to File for Hong Kong IPO
TWSJ·1h ago·3 min read
World News
ECB Expected to Be First Among Peers to Raise Key Rate in Response to Conflict
TWSJ·1h ago·3 min read
Business
German Factory Orders Fell Back in April
TWSJ·1h ago·3 min read
Related
On this beat
Business
Amazon’s $224 Citizen Eco-Drive Luxury watch is a stunning everyday timepiece
THE STREET·6m ago·3 min read
Business
Ingredion to Take Over Tate & Lyle in $3.6 Billion Deal
TWSJ·1h ago·3 min read
Business
Legora’s tech chief says tokenmaxxing is a ‘really stupid way’ to encourage AI use
BI·51m ago·3 min read
Business
All the Ways Europe Is Ditching American Technology
WIRED·2h ago·3 min read